The Real Impact of Rising Rates, and Is Apple About to Break Down? 11/3/22
CNBC's "Fast Money"
00:00
AMGEN, Tops Estimates for Revenue and EBITDA
AMGEN, a biotech company, beat on the top and bottom line. Analysts are very interested in AMG 133, a drug that could help fight obesity. But revenue did fall 1% year over year because of a 5% net price decline as well as a 2% impact from foreign exchange.
Play episode from 18:10
Transcript
